LOS ANGELES, CA--(Marketwired - Jul 10, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) (the "Company") today announced that following its Annual Meeting of Stockholders scheduled for Wednesday, July 17, 2013, the Company will hold an hour-long Q&A Conference Call, on topics unrelated to the Annual Meeting, hosted by Chief Executive Officer Robert H. Lorsch and Chief Financial Officer Ingrid Safranek for investors. The call will start at 1:15 PM Pacific Time / 4:15PM Eastern Time. The Annual Meeting will be held at 10:30AM Pacific Time at MMR's corporate headquarters located at 4401 Wilshire Blvd., Los Angeles, CA, 90010.
According to Bob Lorsch, "There is a lot going on and this type of call is intended to allow stockholders to know about the number of opportunities that we deal with every day. The exciting news is that healthcare professionals are finally being compelled to offer Personal Health Records to their patients as part of their underlying relationship and patient care as a result of Stage 2 Meaningful Use. And based on the Company's patents and other IP, this represents a significant opportunity to open the door to licensing and strategic relationships with vendors and healthcare professionals to utilize our MyMedicalRecords PHRs."
During the live call, interested investors will have the ability to submit questions to management. The Company will be prepared to answer questions pertaining to matters including but not limited to the following:
- The litigation with Walgreen Co., including MMR's plans to seek a stipulation or leave of court to amend its complaint to include claims for infringement of a patent after receiving a June 19th Notice of Allowance for a "Method for Providing a User with a Service for Accessing and Collecting Prescriptions."
- The litigation with Quest Diagnostics, Inc., Jardogs LLC (a wholly owned subsidiary of Allscripts) and/or other similar matters not covered by any confidentiality agreement(s) or litigation privilege.
- Recent positions taken by NEHTA pertaining to MMR's investigation of the possible exploitation of the Company's Australian patents and how it is being dealt with by MMRGlobal's legal team and representatives in Australia as well as MMR's research and investigations in Singapore.
- Licensing opportunities in Japan.
- The status of the Company's Joint Venture with Unis-Tonghe in China.
- The outcome of the recent Surgery Center Management, LLC Appeal in which MMR prevailed and next steps in the case.
- To the extent reasonably possible and subject to existing non-disclosure agreements and understandings, the Company will also answer any questions regarding the status of discussions and negotiations to license its IP to additional EMR vendors including Accenture, which the Company believes participated in the development of electronic and personal medical record systems in Australia and Singapore.
- Sales of MMR's direct-to-consumer products and services, and MMRPro and the continued deliveries of the VISI-MMRPro system pursuant to its agreement with Australian licensee, VisiInc PLC.
If you are planning on attending the Annual Meeting July 17th, please call 310-476-7002 to RSVP for a security pass. To participate in the Conference Call the same day, you will need to register at http://edge.media-server.com/m/p/rpqzb57f/lan/en or by calling Investor Relations at 310-476-7002.
About MMRGlobal, Inc.
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property licenses, potential intellectual property enforcement actions, infringement claims or litigation, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes of intellectual property enforcement actions, infringement claims, litigation or licensing transactions, results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.